Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice

Cited by papers we hold 2

• PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment · 2023
  No notice
• Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.